More on Cepheid (CPHD) Q4 bottom line beats estimates as results were boosted by stronger sales...
Thursday, January 24, 5:09 PM ETMore on Cepheid (CPHD) Q4 bottom line beats estimates as results were boosted by stronger sales and a $5.4M year-earlier charge related to the termination of a patent license. The company issues a downbeat outlook going forward however, projecting weaker-than-expected revenue for 2013. It now sees earnings of between $0.41 to $0.46 per shares on revenue of $375M to $385M. Street expectations were for $0.12 cents and $397M, respectively.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles